HR Execs on the Move

STEMCELL Technologies

www.stemcell.com

 
STEMCELL Technologies is a biotechnology company that develops specialty cell culture media and cell separation products to support research in the fields of immunology, hematology, neuroscience, mesenchymal cell, stem cell and epithelial cell biology. We also provide instruments, cytokines, antibodies, training courses, proficiency testing and contract assay services. Driven by science and a passion for quality, STEMCELL delivers over 2500 products to more than 80 countries worldwide. STEMCELL Technologies provides consistent, unfailing quality and one-on-one assistance to help you succeed. We do this because we love science as much as you do.
  • Number of Employees: 1K-5K
  • Annual Revenue: $10-50 Million
  • www.stemcell.com
  • 1618 Station Street
    Vancouver, BC CAN V6A 1B6
  • Phone: 604.877.0713

Executives

Name Title Contact Details
Michael Warnement
Associate Director Of Sales, Cell Profile
Jennifer Routliffe
Director of Human Resources for North America Profile

Similar Companies

Thomson Research Associates

Thomson Research Associates is a North York, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

NeoPharm

NeoPharm, Inc. is a Waukegan, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Adaptimmune

Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor platform. Established in 2008, the Company aims to utilize the body`s own machinery – the T-cell – to target and destroy cancer cells by using engineered, increased affinity T-cell receptors (TCRs) as a means of strengthening natural patient T-cell responses. Adaptimmune`s lead program is an affinity enhanced TCR therapeutic targeting the NY-ESO cancer antigen. Its NY-ESO TCR therapeutic candidate has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types. In June 2014, Adaptimmune announced that it had entered into a strategic collaboration and licensing agreement with GlaxoSmithKline (GSK) for the development and commercialization of the NY-ESO TCR program in partnership with GSK. In addition, Adaptimmune has a number of proprietary programs and its next TCR therapeutic candidate, directed at MAGE A-10, is scheduled to enter the clinic in 2015. The Company has identified over 30 intracellular target peptides preferentially expressed in cancer cells and is currently progressing eight of these through unpartnered research programs. Adaptimmune has over 150 employees and is located in Oxfordshire, UK and Philadelphia, USA.

Centrillion Biosciences

Centrillion Biosciences is a leading genomic and bioinformatics solution provider.

Merck KGAA

Merck KGAA is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.